Pfizer reported that its mRNA flu vaccine candidate outperformed a traditional flu shot in a large Phase 3 trial.
In a trial of more than 18,000 adults during the 2022–2023 flu season, the mRNA vaccine reduced flu-like illness by 34.5% compared with the standard inactivated vaccine. It also showed stronger protection against influenza A strains and produced higher rates of mild side effects such as injection-site reactions and fever.
The findings represent a notable advancement with potential global implications for future flu vaccine development and patient outcomes.